Correlation between the Warburg effect and progression of triple-negative breast cancer

被引:16
作者
Liu, Shaojun [1 ]
Li, Yuxuan [1 ]
Yuan, Meng [1 ]
Song, Qing [1 ]
Liu, Min [1 ]
机构
[1] Nanjing Univ Chinese Med, Dept Oncol, Suzhou TCM Hosp, Suzhou, Peoples R China
来源
FRONTIERS IN ONCOLOGY | 2023年 / 12卷
基金
中国国家自然科学基金;
关键词
Warburg effect; glycolysis; metabolic plasticity; triple-negative breast cancer; basal-like breast cancer; METABOLIC PATHWAYS; CELL COMPETITION; DRUG-RESISTANCE; TUMOR DORMANCY; METASTASIS; MECHANISMS; INHIBITION; PROMOTES; CYCLE; ACTIVATION;
D O I
10.3389/fonc.2022.1060495
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Triple-negative breast cancer (TNBC) is ineligible for hormonal therapy and Her-2-targeted therapy due to the negative expression of the estrogen receptor, progesterone receptor, and human epidermal growth factor receptor-2. Although targeted therapy and immunotherapy have been shown to attenuate the aggressiveness of TNBC partially, few patients have benefited from them. The conventional treatment for TNBC remains chemotherapy. Chemoresistance, however, impedes therapeutic progress over time, and chemotherapy toxicity increases the burden of cancer on patients. Therefore, introducing more advantageous TNBC treatment options is a necessity. Metabolic reprogramming centered on glucose metabolism is considered a hallmark of tumors. It is described as tumor cells tend to convert glucose to lactate even under normoxic conditions, a phenomenon known as the Warburg effect. Similar to Darwinian evolution, its emergence is attributed to the selective pressures formed by the hypoxic microenvironment of pre-malignant lesions. Of note, the Warburg effect does not disappear with changes in the microenvironment after the formation of malignant tumor phenotypes. Instead, it forms a constitutive expression mediated by mutations or epigenetic modifications, providing a robust selective survival advantage for primary and metastatic lesions. Expanding evidence has demonstrated that the Warburg effect mediates multiple invasive behaviors in TNBC, including proliferation, metastasis, recurrence, immune escape, and multidrug resistance. Moreover, the Warburg effect-targeted therapy has been testified to be feasible in inhibiting TNBC progression. However, not all TNBCs are sensitive to glycolysis inhibitors because TNBC cells flexibly switch their metabolic patterns to cope with different survival pressures, namely metabolic plasticity. Between the Warburg effect-targeted medicines and the actual curative effect, metabolic plasticity creates a divide that must be continuously researched and bridged.
引用
收藏
页数:15
相关论文
共 185 条
  • [1] Common Metabolic Pathways Implicated in Resistance to Chemotherapy Point to a Key Mitochondrial Role in Breast Cancer
    Abad, Etna
    Garcia-Mayea, Yoelsis
    Mir, Cristina
    Sebastian, David
    Zorzano, Antonio
    Potesil, David
    Zdrahal, Zbynek
    Lyakhovich, Alex
    Lleonart, Matilde E.
    [J]. MOLECULAR & CELLULAR PROTEOMICS, 2019, 18 (02) : 231 - 244
  • [2] Activation of glycogenolysis and glycolysis in breast cancer stem cell models
    Abad, Etna
    Samino, Sara
    Yanes, Oscar
    Potesil, David
    Zdrahal, Zbynek
    Lyakhovich, Alex
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 2020, 1866 (10):
  • [3] Na+/H+ exchanger-mediated hydrogen ion extrusion as a carcinogenic signal in triple-negative breast cancer etiopathogenesis and prospects for its inhibition in therapeutics
    Amith, Schammim Ray
    Fliegel, Larry
    [J]. SEMINARS IN CANCER BIOLOGY, 2017, 43 : 35 - 41
  • [4] Targeting Pyruvate Kinase M2 Phosphorylation Reverses Aggressive Cancer Phenotypes
    Apostolidi, Maria
    Vathiotis, Ioannis A.
    Muthusamy, Viswanathan
    Gaule, Patricia
    Gassaway, Brandon M.
    Rimm, David L.
    Rinehart, Jesse
    [J]. CANCER RESEARCH, 2021, 81 (16) : 4346 - 4359
  • [5] Dual treatments targeting IGF-1R, PI3K, mTORC or MEK synergize to inhibit cell growth, induce apoptosis, and arrest cell cycle at G1 phase in MDA-MB-231 cell line
    Ayub, Ayunadirah
    Yip, Wai Kien
    Seow, Heng Fong
    [J]. BIOMEDICINE & PHARMACOTHERAPY, 2015, 75 : 40 - 50
  • [6] Chidamide suppresses the glycolysis of triple negative breast cancer cells partially by targeting the miR-33a-5p-LDHA axis
    Bai, Xiangdong
    Jiang, Hongchuan
    Han, Guohui
    He, Qiang
    [J]. MOLECULAR MEDICINE REPORTS, 2019, 20 (02) : 1857 - 1865
  • [7] Triple-negative breast cancer therapeutic resistance: Where is the Achilles' heel?
    Bai, Xupeng
    Ni, Jie
    Beretov, Julia
    Graham, Peter
    Li, Yong
    [J]. CANCER LETTERS, 2021, 497 : 100 - 111
  • [8] Epigenetic Reprogramming of Cancer-Associated Fibroblasts Deregulates Glucose Metabolism and Facilitates Progression of Breast Cancer
    Becker, Lisa M.
    O'Connell, Joyce T.
    Vo, Annie P.
    Cain, Margo P.
    Tampe, Desiree
    Bizarro, Lauren
    Sugimoto, Hikaru
    McGow, Anna K.
    Asara, John M.
    Lovisa, Sara
    McAndrews, Kathleen M.
    Zielinski, Rafal
    Lorenzi, Philip L.
    Zeisberg, Michael
    Raza, Sughra
    LeBleu, Valerie S.
    Kalluri, Raghu
    [J]. CELL REPORTS, 2020, 31 (09):
  • [9] The metabolism of cancer cells during metastasis
    Bergers, Gabriele
    Fendt, Sarah-Maria
    [J]. NATURE REVIEWS CANCER, 2021, 21 (03) : 162 - 180
  • [10] Tumor-Stroma Mechanics Coordinate Amino Acid Availability to Sustain Tumor Growth and Malignancy
    Bertero, Thomas
    Oldham, William M.
    Grasset, Eloise M.
    Bourget, Isabelle
    Boulter, Etienne
    Pisano, Sabrina
    Hofman, Paul
    Bellvert, Floriant
    Meneguzzi, Guerrino
    Bulavin, Dmitry, V
    Estrach, Soline
    Feral, Chloe C.
    Chan, Stephen Y.
    Bozec, Alexandre
    Gaggioli, Cedric
    [J]. CELL METABOLISM, 2019, 29 (01) : 124 - +